TY - JOUR
T1 - Predictors of greater than 80% 2-year mortality in primary myelofibrosis
T2 - A Mayo Clinic study of 884 karyotypically annotated patients
AU - Tefferi, Ayalew
AU - Jimma, Thitina
AU - Gangat, Naseema
AU - Vaidya, Rakhee
AU - Begna, Kebede H.
AU - Hanson, Curtis A.
AU - Van Dyke, Daniel L.
AU - Caramazza, Domenica
AU - Pardanani, Animesh
PY - 2011/10/27
Y1 - 2011/10/27
N2 - DIPSS-plus (the Dynamic International Prognostic Scoring System-plus) includes 8 risk factors for survival in primary myelofibrosis. In the present study of 884 karyotypically annotated patients with primary myelofibrosis, we sought to identify 1 or 2 parameters that can reliably predict death in the first 2 years of disease. After a median of 8.2 years from time of referral to the Mayo Clinic, 564 deaths (64% of patients in the study) had been recorded. Risk factors associated with > 80% 2-year mortality included monosomal karyotype, inv(3)/i(17q) abnormalities, or any 2 of the following: circulating blasts > 9%, leukocytes ≥ 40 × 109/L, or other unfavorable karyotype. Patients with any 1 of these risk profiles (n = 52) displayed significantly shorter overall survival than those otherwise belonging to a high-risk category per DIPSS-plus (n = 298); respective median survivals were 9 and 23 months (hazard ratio 2.2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches.
AB - DIPSS-plus (the Dynamic International Prognostic Scoring System-plus) includes 8 risk factors for survival in primary myelofibrosis. In the present study of 884 karyotypically annotated patients with primary myelofibrosis, we sought to identify 1 or 2 parameters that can reliably predict death in the first 2 years of disease. After a median of 8.2 years from time of referral to the Mayo Clinic, 564 deaths (64% of patients in the study) had been recorded. Risk factors associated with > 80% 2-year mortality included monosomal karyotype, inv(3)/i(17q) abnormalities, or any 2 of the following: circulating blasts > 9%, leukocytes ≥ 40 × 109/L, or other unfavorable karyotype. Patients with any 1 of these risk profiles (n = 52) displayed significantly shorter overall survival than those otherwise belonging to a high-risk category per DIPSS-plus (n = 298); respective median survivals were 9 and 23 months (hazard ratio 2.2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches.
UR - http://www.scopus.com/inward/record.url?scp=80055075486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055075486&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-08-371096
DO - 10.1182/blood-2011-08-371096
M3 - Article
C2 - 21881047
AN - SCOPUS:80055075486
SN - 0006-4971
VL - 118
SP - 4595
EP - 4598
JO - Blood
JF - Blood
IS - 17
ER -